Zogenix: Zogenix To Present New Long-term Data on FINTEPLA (fenfluramine) in Lennox-Gastaut Syndrome (LGS) at AAN 2022
San Diego, California Two podium and one poster presentation share important new findings on FINTEPLA's safety profile and its impact on non-seizure related benefits for LGS patients &nbs...
Read full article »
Zogenix is a California-based biopharmaceutical company that develops and commercializes transformative therapies for the treatment of epilepsy and mitochondrial diseases.
Read more